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etiologic agent was found, so it was considered that AA was sec-
ondary to HIV. Treatment was initiated with D4T (Stavudine),
3TC (Lamivudine) and Efavirenz achieving undetectable viral load
and increasing CD4 count. Patient also received Erythropoietin
(EPO) and granulocyte-colony stimulating factors (G-CSF) show-
ing an increased number of white blood cells (WBC) but continued
with high transfusional requeirment. We had to stop treatment in
October because of liver failure and lactic acidosis. In November
we changed Stavudine for Tenofovir and reiniciated treatment.
Viral load was always undetectable and CD4 count was  500
cells/ul. However megakaryocytopoiesis and erythropoiesis did not
respond, requiring many transfusions. Coombs Direct Test (CDT)
and Coombs Indirec Test (CIT) were positive.He showed an
immunohaematologic proﬁle with 1 autoantibody (Anti-e) and 3
alloantibodies (Anti-Jka, Anti-Lua, Anti-Cw).
As he had an identical twin, he was submitted to a syngeneic
BMT. Although he was heavily transfused (421 Units ), we did not
want to increase immunosuppression so as not to have viral reac-
tivation. The conditioning regimen consisted of Cy 50 mg/kg/qd x
4, and in order to lower the risk of engrafment failure, peripheral
blood stem cells were used to maximize the number of donor cells
infused (11  106 CD34 cells/kg). At the transplantation the
patient was in high-risk. The antiretroviral treatment was not
discontinued. No graft versus host disease (GVHD) proﬁlaxis was
needed. Neutrophils and platelets engrafted at day 11.
After 10 months of transplantation he continues in complete
haematologic remission. Serum antibodies, CDT and CIT are
negative.Viral load remains undetectable (b-DNA).
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Hematology, Rigshospitalet, Copenhagen, Denmark; 2Department of
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Graft rejection after hematopoietic cell transplantation (HCT)
with nonmyeloablative conditioning is a rare event and a serious
clinical problem. Manifest (N8) and imminent rejection (N4)
in a cohort of 98 consecutive patients with hematological malig-
nancies were analyzed. The patients were conditioned with ﬂu-
darabine 30 mg/m2 and 2 Gy of total body irradiation and trans-
planted with peripheral blood stem cells. Intervention aiming at
reversing imminent rejection with donor lymphocyte infusion
(DLI) alone or preceded by immunosuppression with pentostatin
was attempted with highly variable results. Chimerism analysis is
the standard method to monitor engraftment and rejection. In the
present report we have evaluated the product of absolute T cell
counts and chimerism, which we have termed absolute chimerism,
for monitoring patients with manifest or imminent rejection. The
results suggest that recipient T cell counts  donor T cell counts
and increasing recipient T cells post-transplant are risk factors for
rejection. Peaks of absolute recipient CD4 and/or CD8 T cell
counts were seen in relation to rejection and peaks of donor CD4
and/or CD8 T cells were seen in connection with acute graft-
versus-host disease. Furthermore absolute chimerism plots in some
cases clearly indicate the time-interval where disappearance of
recipient T cells takes place. These ﬁndings may be of importance
for understanding the cellular mechanisms underlying alloreactiv-
ity. Absolute chimerism plots point to a variable immunosuppres-
sive effect of pentostatin on recipient T cells as explanation for
pentostatin/DLI-failure in reversing rejection. We conclude that
absolute chimerism plots can contribute signiﬁcant new informa-
tion of value for routine monitoring of patients with mixed chi-
merism as well as for research purposes. Following rejection pa-
tients are at risk of dying from infections and progression/relapse
of their malignancy. Retransplantation is feasible and well tolerated
after HCT with nonmyeloablative conditioning. In patients with
imminent graft rejection retransplantation is an attractive alterna-
tive to DLI or immunosuppression/DLI.
260
AN IMPROVED METHOD FOR ENGRAFTMENT MONITORING USING
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The commonly used engraftment monitoring method of short
tandem repeat (STR) ampliﬁcation following allogeneic hemato-
poietic stem cell transplantation (HSCT) is hampered by several
shortcomings affecting sensitivity, accuracy, reproducibility, and
results interpretation. In an effort to provide a better solution, we
have developed a truly quantitative, real-time PCR method. Real-
time PCR technology is ideally suited for this application because
it is highly sensitive and quantitatively much more accurate and
precise than STR analysis. It is not affected by problems inherent
to STR ampliﬁcation and analysis such as plateau bias, preferential
allele ampliﬁcation, and stutter artifacts. With our method,
genomic mixtures are easily resolved, and analysis is straightfor-
ward and automatable. Success and maintenance of allogeneic
HSCT may be enhanced with such an improved engraftment
monitoring method.
We have developed a panel of non-repetitive polymorphic mark-
ers, with representatives on all chromosomes, useful for identifying
differences between recipient and donor pairs. Our statistical anal-
yses given allele frequencies in multiple human populations dem-
onstrate that with relatively high minor allele frequencies, a limited
panel of markers can be assembled which would have high prob-
ability of providing informative markers that could distinguish
HLA-matched individuals. The testing process ﬁrst requires that
the donor and recipient genomic DNA be screened in order to
identify informative markers between the two genomes. Once
deﬁned, these markers are used post-transplant to quantify the
relative percentage of recipient genetic material in the donor back-
ground. Compared to the current STR assays, our method shows
a greater than 100-fold increase in sensitivity with excellent accu-
racy and precision at concentrations as low as 0.01% recipient in a
background of 99.99% donor DNA. Given the reproducibility of
results and ease of data analysis, this approach provides the means
for standardization within a testing lab as well as between testing
centers, which cannot be accomplished with homebrew and off-
label methods such as STR analysis. From a clinical perspective,
improved sensitivity, accuracy, and precision provide the potential
to detect disease relapse or transplant rejection at a much earlier
stage. This information may be useful for improving decisions
related to maintenance treatments such as GVHD prophylaxis
and/or donor lymphocyte infusion.
261
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We report a retrospective study of the clinical features and
outcome for 32 allogeneic stem cell transplants (AlloSCT) from
HLA-matched sibling donors in severe aplastic anemia condi-
tioned with 200 mg/kg of cyclophosphamide plus 90 mg/kg of
horse antithymocyte globulin (ATG) in 17 patients and 120 mg/kg
of cyclophosphamide plus 12 mg/kg of busulfan (Bu) in 15 patients,
at Hospital Sa˜o Paulo and Hospital Santa Marcelina, from No-
vember 1993 to August 2003. Considering high cost of ATG and
the difﬁculty to obtain it for the majority of our centers, the
objective was to compare clinical variables as age, sex, engraftment,
interval of time from diagnosis to AlloSCT, number infused of
total nuclear cells, previous transfusions, occurrence of acute and
chronic GVHD, infections, acute and late graft rejection and
overall survival, between these two conditioning regimens. We
analyzed the long-term hematopoietic chimerism by FISH, using a
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